Developer docs
API playgroundTry for free, no card

Search company profiles

Sano Genetics

Full company profile

uuid0000o92

Namestring
Sano Genetics
Legal namestring
Sano Genetics Limited
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Sano Genetics Limited is a Cambridge, UK-based precision medicine technology company founded in 2017 by three University of Cambridge PhD students (Patrick Short, Charlotte Guzzo, and William Jones). It operates a 360-degree cloud platform that integrates patient recruitment, prescreening and digital consent, at-home saliva-based DNA testing with end-to-end logistics, electronic medical record retrieval (up to seven years of longitudinal history), biomarker screening, customized patient engagement portals, and study analytics into a single digital workflow aimed at pharmaceutical, biotech, CRO, patient advocacy, and NHS research customers.

Underlying technology centers on a privacy- and security-first architecture (ISO27001, HIPAA, GDPR, Cyber Essentials certified, with optional dedicated cloud deployment) combined with a proprietary patient database and a network of patient advocacy group partnerships that the company uses for recruitment. Specialized product extensions include the DREAM (Data Repository, Exchange, and Analytics platforM) built for the Lupus Research Alliance's Lupus Nexus program, with Lifebit as technology partner, and disease-specific programs spanning MASH, Parkinson's, ALS, Long COVID, and a UK population genomics initiative. Quantified outcomes claimed by the company include up to 10x faster study timelines, up to 55% cost reduction, and 3x faster participant enrollment versus traditional methods.

The business model is a consultative, quote-based enterprise sale with multi-year contracts priced per study; the company does not publish standard pricing tiers. Go-to-market combines direct enterprise field sales with inside sales, supported by content marketing, webinars, case studies, the in-house Genetics Podcast, and participation in industry events. The company is venture-backed (approximately $22M total disclosed funding across seed, Series A, and a Series A follow-on led by Plural in January 2024), reported 5x ARR growth in 2023, and operates with roughly 40 employees across the UK and the US.

Short descriptiontext

Sano Genetics is a Cambridge, UK-based precision medicine platform company that sells a 360-degree cloud workflow covering patient recruitment, at-home DNA testing, EMR retrieval, and long-term engagement to pharmaceutical, biotech, CRO, patient advocacy, and NHS research customers under quote-based, multi-year enterprise contracts.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision medicine platform, clinical trial recruitment, genetic testing services, patient engagement software, biomarker screening services
Industry5 codes
PRIMARYHLAAANAI
Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials)
SECONDARYHLAGAJAF
Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLACAOAO
Biostatistics, Statistical Computing & Clinical Programming (SAS/R/Pipelines)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
NAICS code4 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Custom Computer Programming Services541511
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
  • Services-Computer Programming, Data Processing, Etc.7370
Product category
Precision Medicine Platform
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Platform and Services Subscription
TypeSubscription Recurring
Description

Sano Genetics offers its 360-degree platform and associated services (recruitment support, prescreening, DNA testing, EMR retrieval, patient engagement) to pharmaceutical companies, biotechs, and patient advocacy groups. Pricing is customized and quote-based, tailored to each study's goals and scope.

sanogenetics.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Custom / Tailored Project Plans
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Pricing is customized per project. The company offers tailored proposals with full timelines and detailed budgets. No public price tiers or standard rates are disclosed.

sanogenetics.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Sano Genetics operates a 360-degree cloud-based precision medicine platform that connects patient recruitment, prescreening, digital consent, at-home saliva DNA testing, electronic medical record retrieval, biomarker screening, and long-term patient engagement in one unified workflow. The company sells this platform plus associated services (protocol development, recruitment support, DNA testing, EMR retrieval, and patient engagement) to pharmaceutical companies, biotechs, patient advocacy groups, CROs, and NHS/academic research sites running precision medicine studies. Pricing is customized per project and delivered through multi-year subscriptions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Up to 10x faster study timelines for precision medicine teams
+4 more records
Product and service1 record
1Sano 360-Degree Precision Medicine Platform
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Collaborated with the Lupus Research Alliance and Lifebit to build the DREAM (Data Repository, Exchange, and Analytics platforM) platform as part of the Lupus Nexus program. Sano Genetics built and maintains the patient-facing engagement platform for those living with lupus to participate in research.

Strategic tierFlagshipTypeTechnology or Integration
Description

Partnered with Sano Genetics on the Lupus Nexus DREAM platform. Lifebit implemented and manages the knowledge-exchange and analytics platform for researchers and clinicians, while Sano drives patient engagement.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Sano Genetics partnered with Predictive Health Intelligence on the LiveWell precision liver study, using PHI's hepatoSIGHT case-finding software combined with Sano's platform for recruitment, genetic testing, and participant engagement.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Clinical oversight and research delivery partner for the LiveWell study, supporting enrollment of 996 participants from a single NHS site. Provided access to NHS patient data and clinical infrastructure.

5Tawazun Health
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Delivered FibroScan liver assessments as part of the LiveWell study, enabling non-invasive liver diagnostics for participants identified at risk. A CQC-regulated specialist provider of liver assessments.

sanogenetics.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Antidote (Eversana)
TypeDirect peer
Description

Antidote is a patient recruitment and clinical trial matching platform that was acquired by Eversana. It is directly comparable to Sano Genetics' patient finding and prescreening capabilities for precision medicine trials, although without Sano's integrated genetic testing and EMR retrieval.

TypeDirect peer
Description

Trial Library uses AI to match patients to precision medicine and oncology clinical trials, directly competing with Sano's patient recruitment and biomarker screening capabilities for pharma sponsors.

3Mendel Health
TypeDirect peer
Description

Mendel applies AI to structured and unstructured medical records for clinical trial patient matching and real-world data generation. It competes most directly with Sano's EMR retrieval, prescreening, and analytics layer within the precision medicine trial workflow.

4Deep 6 AI
TypeDirect peer
Description

Deep 6 AI uses AI to mine EHR data for patient cohort identification and clinical trial recruitment. It overlaps with Sano's EMR-based prescreening and patient finding capabilities for pharma and biotech sponsors.

TypeBroad incumbent
Description

IQVIA is the world's largest CRO with extensive capabilities across clinical trial design, patient recruitment, real-world evidence, and lab services. It is a broad incumbent that competes with Sano on enterprise pharma trial enablement, though without Sano's focus on genetic testing and patient-facing engagement.

TypeBroad incumbent
Description

Labcorp Drug Development (spun off as Fortrea) is a global CRO offering clinical trial services plus central laboratory and diagnostics capabilities. Its integrated lab and trial services overlap with Sano's genetic testing and trial enablement offerings, though at vastly greater scale and breadth.

TypeBroad incumbent
Description

Medidata provides the industry-leading clinical trial technology platform (Rave EDC, eCOA, RTSM, etc.). It is an incumbent in clinical trial informatics that competes broadly with Sano's e-consent and study management capabilities, though it does not offer genetic testing or patient recruitment.

TypeEmerging player
Description

Seqster is a patient-centric health data platform that aggregates genomic, clinical, and wearable data from multiple sources. It is comparable to Sano's patient-driven data integration layer, though its primary focus is longitudinal patient data rather than trial recruitment.

TypeEmerging player
Description

Color Health is a genetics and preventive health company offering at-home genetic testing, screening programs, and clinical research services. Its clinical research arm overlaps with Sano's DNA testing and population genomics programs, though Color focuses more on employer/payer screening.

TypeEmerging player
Description

Castor is a clinical trial technology platform offering EDC, ePRO, eConsent, and decentralized trial capabilities. It competes with the study management and digital consent portions of Sano's platform for sponsors running decentralized and precision medicine trials.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sano Genetics

Precision Medicine Platformsanogenetics.com

Sano Genetics is a Cambridge, UK-based precision medicine platform company that sells a 360-degree cloud workflow covering patient recruitment, at-home DNA testing, EMR retrieval, and long-term engagement to pharmaceutical, biotech, CRO, patient advocacy, and NHS research customers under quote-based, multi-year enterprise contracts.

What Sano Genetics does

Sano Genetics Limited is a Cambridge, UK-based precision medicine technology company founded in 2017 by three University of Cambridge PhD students (Patrick Short, Charlotte Guzzo, and William Jones). It operates a 360-degree cloud platform that integrates patient recruitment, prescreening and digital consent, at-home saliva-based DNA testing with end-to-end logistics, electronic medical record retrieval (up to seven years of longitudinal history), biomarker screening, customized patient engagement portals, and study analytics into a single digital workflow aimed at pharmaceutical, biotech, CRO, patient advocacy, and NHS research customers.

Underlying technology centers on a privacy- and security-first architecture (ISO27001, HIPAA, GDPR, Cyber Essentials certified, with optional dedicated cloud deployment) combined with a proprietary patient database and a network of patient advocacy group partnerships that the company uses for recruitment. Specialized product extensions include the DREAM (Data Repository, Exchange, and Analytics platforM) built for the Lupus Research Alliance's Lupus Nexus program, with Lifebit as technology partner, and disease-specific programs spanning MASH, Parkinson's, ALS, Long COVID, and a UK population genomics initiative. Quantified outcomes claimed by the company include up to 10x faster study timelines, up to 55% cost reduction, and 3x faster participant enrollment versus traditional methods.

The business model is a consultative, quote-based enterprise sale with multi-year contracts priced per study; the company does not publish standard pricing tiers. Go-to-market combines direct enterprise field sales with inside sales, supported by content marketing, webinars, case studies, the in-house Genetics Podcast, and participation in industry events. The company is venture-backed (approximately $22M total disclosed funding across seed, Series A, and a Series A follow-on led by Plural in January 2024), reported 5x ARR growth in 2023, and operates with roughly 40 employees across the UK and the US.

Sano Genetics firmographics

Firmographics
Name
Sano Genetics
Legal name
Sano Genetics Limited
Website
https://sanogenetics.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Sano Genetics is a Cambridge, UK-based precision medicine platform company that sells a 360-degree cloud workflow covering patient recruitment, at-home DNA testing, EMR retrieval, and long-term engagement to pharmaceutical, biotech, CRO, patient advocacy, and NHS research customers under quote-based, multi-year enterprise contracts.
Ownership category
akta.pro rank

Sano Genetics industry classification

Industry
Product category
Precision Medicine Platform
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Custom Computer Programming Services (541511)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731), Services-Computer Programming, Data Processing, Etc. (7370)
akta.pro industry
PRIMARYHLAAANAI
Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials)
SECONDARYHLAGAJAF
Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLACAOAO
Biostatistics, Statistical Computing & Clinical Programming (SAS/R/Pipelines)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)

Keywords

  • Precision medicine platform
  • Clinical trial recruitment
  • Genetic testing services
  • Patient engagement software
  • Biomarker screening services

Where Sano Genetics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Sano Genetics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Platform and Services Subscription: Sano Genetics offers its 360-degree platform and associated services (recruitment support, prescreening, DNA testing, EMR retrieval, patient engagement) to pharmaceutical companies, biotechs, and patient advocacy groups. Pricing is customized and quote-based, tailored to each study's goals and scope.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractCustom / Tailored Project Plans

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Sano Genetics product offering

Product offering

Core offering

Sano Genetics operates a 360-degree cloud-based precision medicine platform that connects patient recruitment, prescreening, digital consent, at-home saliva DNA testing, electronic medical record retrieval, biomarker screening, and long-term patient engagement in one unified workflow. The company sells this platform plus associated services (protocol development, recruitment support, DNA testing, EMR retrieval, and patient engagement) to pharmaceutical companies, biotechs, patient advocacy groups, CROs, and NHS/academic research sites running precision medicine studies. Pricing is customized per project and delivered through multi-year subscriptions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Sano 360-Degree Precision Medicine Platform

Quantifiable outcome

  • Up to 10x faster study timelines for precision medicine teams
  • +4 more outcomes

Companies that use Sano Genetics

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Sano Genetics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature7 records

Sano Genetics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered flagship and supporting.

  • Lupus Research AllianceflagshipStrategic or Co-development PartnerCollaborated with the Lupus Research Alliance and Lifebit to build the DREAM (Data Repository, Exchange, and Analytics platforM) platform as part of the Lupus Nexus program. Sano Genetics built and maintains the patient-facing engagement platform for those living with lupus to participate in research.
  • LifebitflagshipTechnology or IntegrationPartnered with Sano Genetics on the Lupus Nexus DREAM platform. Lifebit implemented and manages the knowledge-exchange and analytics platform for researchers and clinicians, while Sano drives patient engagement.
  • Predictive Health IntelligenceflagshipStrategic or Co-development PartnerSano Genetics partnered with Predictive Health Intelligence on the LiveWell precision liver study, using PHI's hepatoSIGHT case-finding software combined with Sano's platform for recruitment, genetic testing, and participant engagement.
  • Somerset NHS Foundation TrustflagshipStrategic or Co-development PartnerClinical oversight and research delivery partner for the LiveWell study, supporting enrollment of 996 participants from a single NHS site. Provided access to NHS patient data and clinical infrastructure.
  • Tawazun HealthsupportingStrategic or Co-development PartnerDelivered FibroScan liver assessments as part of the LiveWell study, enabling non-invasive liver diagnostics for participants identified at risk. A CQC-regulated specialist provider of liver assessments.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Sano Genetics competitors and assessment

Company assessment

Direct peers

  • Antidote (Eversana): Antidote is a patient recruitment and clinical trial matching platform that was acquired by Eversana. It is directly comparable to Sano Genetics' patient finding and prescreening capabilities for precision medicine trials, although without Sano's integrated genetic testing and EMR retrieval.
  • Trial Library: Trial Library uses AI to match patients to precision medicine and oncology clinical trials, directly competing with Sano's patient recruitment and biomarker screening capabilities for pharma sponsors.
  • Mendel Health: Mendel applies AI to structured and unstructured medical records for clinical trial patient matching and real-world data generation. It competes most directly with Sano's EMR retrieval, prescreening, and analytics layer within the precision medicine trial workflow.
  • Deep 6 AI: Deep 6 AI uses AI to mine EHR data for patient cohort identification and clinical trial recruitment. It overlaps with Sano's EMR-based prescreening and patient finding capabilities for pharma and biotech sponsors.

Broad incumbents

  • IQVIA: IQVIA is the world's largest CRO with extensive capabilities across clinical trial design, patient recruitment, real-world evidence, and lab services. It is a broad incumbent that competes with Sano on enterprise pharma trial enablement, though without Sano's focus on genetic testing and patient-facing engagement.
  • Labcorp Drug Development (Fortrea): Labcorp Drug Development (spun off as Fortrea) is a global CRO offering clinical trial services plus central laboratory and diagnostics capabilities. Its integrated lab and trial services overlap with Sano's genetic testing and trial enablement offerings, though at vastly greater scale and breadth.
  • Medidata (Dassault Systèmes): Medidata provides the industry-leading clinical trial technology platform (Rave EDC, eCOA, RTSM, etc.). It is an incumbent in clinical trial informatics that competes broadly with Sano's e-consent and study management capabilities, though it does not offer genetic testing or patient recruitment.

Emerging players

  • Seqster: Seqster is a patient-centric health data platform that aggregates genomic, clinical, and wearable data from multiple sources. It is comparable to Sano's patient-driven data integration layer, though its primary focus is longitudinal patient data rather than trial recruitment.
  • Color Health: Color Health is a genetics and preventive health company offering at-home genetic testing, screening programs, and clinical research services. Its clinical research arm overlaps with Sano's DNA testing and population genomics programs, though Color focuses more on employer/payer screening.
  • Castor: Castor is a clinical trial technology platform offering EDC, ePRO, eConsent, and decentralized trial capabilities. It competes with the study management and digital consent portions of Sano's platform for sponsors running decentralized and precision medicine trials.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Sano Genetics social profiles

Digital presence

Sano Genetics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sano Genetics leadership team

Management profile

Number of profiles

Profiles12 records

Sano Genetics funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sano Genetics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sano Genetics

What does Sano Genetics do?

Sano Genetics operates a 360-degree cloud-based precision medicine platform that connects patient recruitment, prescreening, digital consent, at-home saliva DNA testing, electronic medical record retrieval, biomarker screening, and long-term patient engagement in one unified workflow. The company sells this platform plus associated services (protocol development, recruitment support, DNA testing, EMR retrieval, and patient engagement) to pharmaceutical companies, biotechs, patient advocacy groups, CROs, and NHS/academic research sites running precision medicine studies. Pricing is customized per project and delivered through multi-year subscriptions.

Is Sano Genetics a public or private company?

Sano Genetics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Sano Genetics founded?

Sano Genetics was founded in 2017. It employs 11 to 50 people.

Where is Sano Genetics based?

Sano Genetics is headquartered in Cambridge, United Kingdom, in the Europe region.

How does Sano Genetics make money?

One revenue line is on record: platform and Services Subscription.

Who are Sano Genetics's main competitors?

Direct peers on record are Antidote (Eversana), Trial Library, Mendel Health and Deep 6 AI. Broad incumbents are IQVIA, Labcorp Drug Development (Fortrea) and Medidata (Dassault Systèmes). Emerging players are Seqster, Color Health and Castor.

Does Sano Genetics have an API?

No public API is recorded for Sano Genetics.

What industry is Sano Genetics in?

Sano Genetics's product category is Precision Medicine Platform. Its primary akta.pro industry code is HLAAANAI, Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials), with a secondary code of HLAGAJAF, Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D). Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogBioMendics Receives FDA Fast Track Designation for BM-3103 (TolaSure® Gel™) for Epidermolysis Bullosa SimplexBioMendics received FDA Fast Track designation for BM-3103 (TolaSure Gel) for Epidermolysis Bullosa Simplex, alongside Orphan Drug and Rare Pediatric Disease designations. The company is advancing the TAMES-02 Phase 2 trial with Northwestern and Stanford investigators. BioMendics plans to share progress at BIO 2026.Sanogenetics20 clinical trial patient recruitment companies to drive your research forward, and how to choose oneThe article outlines the significant challenges and costs associated with clinical trial patient recruitment, noting that delays often stem from difficulties in finding eligible participants. It provides a guide on selecting recruitment partners based on expertise, strategy, and metrics, while listing 20 specialized companies such as Sano Genetics, OneStudyTeam, and Science 37 that offer various digital and decentralized solutions.ForbesHow To Partner With Big Business When You’re A StartupStartups can partner with large corporations by identifying decision-makers and demonstrating value, as advised by founders of Sano Genetics, Kimai, and Seaglow Media. Cold outreach and agility are highlighted as key strategies, with examples of securing listings and sales. The advice emphasizes building credibility and managing long sales cycles.outsourcing-pharma.comSano Genetics raises a further $11.4 million for its 'precision medicine revolution'Sano Genetics raised $11.4 million in a new funding round led by Plural, bringing total funding to $22 million. The company reported 5x ARR growth in 2023, doubled its headcount to 62, and expanded into the large pharmaceutical market. It plans to use the funds to integrate AI, expand globally, and support precision medicine trials.WebrazziSağlık teknolojilerine odaklanan Sano Genetics, 11,4 milyon dolar yatırım aldıSano Genetics, Plural Ventures liderliğinde 11,4 milyon dolarlık bir yatırım turu tamamladı. Şirket, bu fonları ürün geliştirmek ve küresel ölçekte faaliyetlerini genişletmek amacıyla kullanmayı planlıyor.PharmiWeb.comSano Genetics raises $11.4 million led by Plural to power precision medicine revolution with seamless trialsSano Genetics has raised $11.4 million in funding led by Plural, bringing its total capitalization to $22 million to support the expansion of its AI-driven software platform for precision medicine clinical trials. The company reported five-fold year-over-year growth in annual recurring revenue and is currently serving four major pharmaceutical companies while connecting patients across the UK, US, Australia, and Canada.Tech.euSano Genetics raises $11.4M to advance precision medicine clinical trialsSano Genetics raised $11.4 million led by Plural to advance its precision medicine clinical trial platform. The funding brings total raised to $22 million and will support AI integration and expansion. The company has supported over 20 studies and plans to use funds for predictive and preventive genetics programs.HIT ConsultantSano Genetics Secures $11.4M for Precision Medicine ResearchSano Genetics secured $11.4M in new funding led by Plural, bringing total funding to $22M. The company's platform connects patients across four countries with clinical trials up to three times faster than traditional methods. It plans to integrate LLMs and AI tools to drive productivity.SanogeneticsSano Genetics raises $11.4 million led by Plural to power precision medicine revolution with seamless trialsSano Genetics has raised $11.4 million in funding led by Plural, bringing its total capital to $22 million to expand its AI-driven precision medicine clinical trial platform. The company reported five-fold year-over-year growth in annual recurring revenue and currently serves four of the top 20 pharmaceutical companies. The new capital will be used to further automate processes, integrate large language models, and expand operations into additional countries.UktechnewsSano Genetics secures £8.95 million Series A Follow On investment led by PluralSano Genetics has secured £8.95 million in Series A Follow On investment led by Plural, bringing its total funding to $22 million to support AI integration and global expansion. The Cambridge-based software company reported fivefold year-on-year ARR growth in 2023 and now serves four major pharmaceutical companies with its precision medicine clinical trial platform.